stoxline Quote Chart Rank Option Currency Glossary
  
Qualigen Therapeutics, Inc. (QLGN)
0.2732  -0.007 (-2.43%)    05-30 16:00
Open: 0.276
High: 0.281
Volume: 57,655
  
Pre. Close: 0.28
Low: 0.2728
Market Cap: 2(M)
Technical analysis
2024-05-30 4:43:58 PM
Short term     
Mid term     
Targets 6-month :  0.35 1-year :  0.39
Resists First :  0.3 Second :  0.33
Pivot price 0.28
Supports First :  0.25 Second :  0.21
MAs MA(5) :  0.28 MA(20) :  0.28
MA(100) :  0.39 MA(250) :  0.69
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  26.9 D(3) :  38.2
RSI RSI(14): 39.5
52-week High :  1.25 Low :  0.25
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ QLGN ] has closed above bottom band by 14.6%. Bollinger Bands are 53.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.28 - 0.28 0.28 - 0.28
Low: 0.27 - 0.27 0.27 - 0.27
Close: 0.27 - 0.27 0.27 - 0.28
Company Description

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Headline News

Thu, 30 May 2024
Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination - GlobeNewswire

Sun, 26 May 2024
Qualigen Therapeutics (NASDAQ:QLGN) Trading Up 6.1% - Defense World

Tue, 09 Apr 2024
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in ... - GlobeNewswire

Thu, 28 Mar 2024
Qualigen Therapeutics Ends Deal with Pan-RAS Holdings - TipRanks.com - TipRanks

Tue, 27 Feb 2024
Qualigen Therapeutics Secures Investment and Expands Financing Options - TipRanks.com - TipRanks

Wed, 27 Sep 2023
Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023 - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 6 (M)
Shares Float 6 (M)
Held by Insiders 11.5 (%)
Held by Institutions 2.6 (%)
Shares Short 43 (K)
Shares Short P.Month 80 (K)
Stock Financials
EPS -2.47
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.39
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -67 %
Return on Equity (ttm) -374.5 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.8
Qtrly Earnings Growth 0 %
Operating Cash Flow -10 (M)
Levered Free Cash Flow -4 (M)
Stock Valuations
PE Ratio -0.12
PEG Ratio 0
Price to Book value -0.71
Price to Sales 0
Price to Cash Flow -0.17
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android